EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination

Clement Twumasi iD, Sally Moore iD, Ross Sadler iD, Sally Jeans, Sherin Varghese iD, Alison Turner iD, Gaurav Agarwal iD, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock iD und 11 weitere

European Journal of Haematology · 2024-04 · 112 (4) · 547-553

DOI: 10.1111/ejh.14143 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Haematology, online erschienen am 20.12.2023. Verfasst von Clement Twumasi und 22 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Imperial College London, Oxford, UK. Hauptthemen laut MEDLINE: COVID-19, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Blood Cancer Vaccine Consortium, Myeloma UK, Janssen UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe determinants of persisting humoral and cellular immune response to the second COVID‐19 vaccination among patients with myeloma.

Methods

This is a prospective, observational study utilising the RUDYstudy.org platform. Participants reported their second and third COVID‐19 vaccination dates. Myeloma patients had an Anti‐S antibody level sample taken at least 21 days after their second vaccination and a repeat sample before their third vaccination.

Results

60 patients provided samples at least 3 weeks (median 57.5 days) after their second vaccination and before their third vaccination (median 176.0 days after second vaccine dose). Low Anti‐S antibody levels (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Multiple MyelomaHumansT-LymphocytesCOVID-19 VaccinesAntibodiesVaccinationAntibodies, ViralImmunity, Cellular

Stichwörter der Autor:innen

COVID-19 vaccinationmyelomapredictors

Substanzen

COVID-19 VaccinesAntibodiesAntibodies, Viral

Autor:innen und Institutionen

  • School of Public Health, Imperial College London, Oxford, UK.
  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Bath Royal United Hospitals, Oxford University Hospitals NHS Trust, Bath, UK.
  • Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, UK.
  • The Botnar Research Centre, Headington, UK.
  • Medical Sciences Division, University of Oxford, Oxford, UK.

ORCID-Profile: Clement Twumasi, Sally Moore, Ross Sadler, Sherin Varghese, Alison Turner, Gaurav Agarwal, Stella Bowcock, Udo Oppermann, Gordon Cook, Mark Drayson, Supratik Basu, Sarah Gooding, Muhammad K Javaid, Karthik Ramasamy

Förderung

  • Blood Cancer Vaccine Consortium
  • Myeloma UK
  • Janssen UK
  • National Institute for Health Research
  • National Institute for Health and Care Research

Zitieren

APA

Twumasi, C., Moore, S., Sadler, R., Jeans, S., Varghese, S., Turner, A., Agarwal, G., Larham, J., Gray, N., Carty, O., Barrett, J., Bowcock, S., Oppermann, U., Gamble, V., Cook, G., Kyriakou, C., Drayson, M., Basu, S., McDonald, S., …, & Ramasamy, K. (2024). Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination. European Journal of Haematology, 112(4), 547-553. https://doi.org/10.1111/ejh.14143

Vancouver

Twumasi C, Moore S, Sadler R, Jeans S, Varghese S, Turner A, et al. Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination. European Journal of Haematology. 2024;112(4):547-553. doi:10.1111/ejh.14143

BibTeX
@article{Twumasi2024,
  author = {Twumasi, Clement and Moore, Sally and Sadler, Ross and Jeans, Sally and Varghese, Sherin and Turner, Alison and Agarwal, Gaurav and Larham, Jemma and Gray, Nathanael and Carty, Oluremi and Barrett, Joe and Bowcock, Stella and Oppermann, Udo and Gamble, Vicky and Cook, Gordon and Kyriakou, Chara and Drayson, Mark and Basu, Supratik and McDonald, Sarah and McKinley, Shelagh and Gooding, Sarah and Javaid, Muhammad K and Ramasamy, Karthik},
  title = {Determinants of durable humoral and T cell immunity in myeloma patients following COVID ‐19 vaccination},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {112},
  number = {4},
  pages = {547--553},
  doi = {10.1111/ejh.14143}
}
Kostenlos starten →